Systemic reduced‐dose alteplase for diffuse pulmonary thrombi in a COVID‐19 patient

Abstract

Abstract Pulmonary embolism has a high frequency in COVID‐19 patients admitted to the intensive care unit. Low level of fibrinolysis is one of the asserted contributors to a prothrombotic state in COVID‐19. Thrombotic coagulopathy is mostly encountered as diffuse pulmonary thrombi. Diffuse pulmonary microemboli was treated successfully with reduced dose thrombolysis.

Keywords

• alteplase
• computed tomography
• COVID‐19
• diffuse pulmonary microthrombi
• pulmonary embolism